Introduction to inflammation, autoimmune disease, nsaids and Ra pathophysiology Flashcards

1
Q

What is autoimmunity?

A

Autoimmunity is the immune response against the body’s self antigens. It occurs when the body’s self tolerance mechanisms fails.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

How is self tolerance acheived?

A
  • Segregation of antigens; physical barriers and immune privileged sites.
  • Central tolerance: limits the development of B and T cells
  • Peripheral tolerance: regulates autoreactive cells in circulation.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Why do we have both central and peripheral tolerance.?

A
  • Not all self antigens are expressed in the central lymphoid organs where the negative selection occurs.
  • There is a threshold requirement for affinity to self antigens before deletion is triggered so some weakly self reactive cells survive.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What is central tolerance for T lymphocytes?

A

As the self antigens are presented to the T cells, we need the weak binding. If the T cell binds strongly to the self antigens, it undergoes apoptosis as these are possible autoreactive T cells. If it binds moderately to it, it becomes a T regulatory cells. If it binds weakly to the self antigens, it survives. Central tolerance of T cells occurs in the thymus.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Describe central tolerance for B lymphocytes?

A

As the self antigens are presented to the B cells in the bone marrow, the one that binds to the antigen with high avidity undergoes receptor editing where they express new light chains in order to minimise it, if it still has high avidity, it undergoes apoptosis and dies. If the B cell binds to the self antigen with low avidity, it becomes anergic meaning it will not bind to that specific antigen again in its lifespan.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Describe peripheral tolerance for T cells?

A

As some autoreactive T cells escape the central tolerance in the thymus and finds their way into the blood circiulation, since they are auto-reactive they can bind to the self antigens found in the peripheral circulation but the body has a way of stopping this and this is through peripheral tolerance. When the autoreactive T cell binds to the self antigen, T regulatory cells come and prevent the co stimulation with the self antigen. It does this through three main ways
- Anergy: functional unresponsiveness without the necessary costimulatory signals.
- suppression: Block the activation by the T regulatory cells.
Deletion: apoptosis through the release of fas ligand which binds to the fas receptor and causes apoptosis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Describe the peripheral tolerance for B cells?

A

As the autoreactive B cells bind to the self antigens, this prevents Th 2 cells from releasing cytokines which activate the B cell and the B cell to produce autoantibodies and hence either becomes anergic, die through apoptosis or is regulated through inhibitory receptors.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What causes autoimmune diseases ?

A

Autoimmune diseases occur as multiple layers of self tolerance fails or are dysfunctional. since antigen cannot be eliminated, response is sustained.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Is autoimmune disease more frequent in men or women and why?

A

Autoimmune diseases is more frequent in women than men and this has something to do with oestrogen levels in females which influences immune system to predispose to autoimmune diseases.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Does the presence of one autoimmune disease increase the chance for more autoimmune disease?

A

Yes; the presence of one autoimmune disease does increase the chance for another autoimmune disease to occur.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

How are genes associated with autoimmunity?

A

There is a strong genetic component in autoimmune diseases. Most autoimmune diseases are polygenic and affected individuals inherit multiple genetic polymorphisms that contribute to disease susceptibility. Also there is a strong association of MHC class II with the disease.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What are the challenges in treating autoimmune diseases?

A

Because there is not only one gene involved;
- There is difficulty in relating complex genotypes to phenotypic and functional abnormalities to better understand pathogenesis.
- Identified disease-associated polymorphisms have small effects, therefore little predictive value.
- Because of small effects of any one gene, targeting these genes therapeutically is unlikely to have significant benefit.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Describe the multiple layers of self tolerance its site of action and mechanism?

A
  • Central tolerance: its mechanism is deletion editing and it occurs at the thymus and bone marrow.
  • Antigen segregation: its mechanism is barrier to self antigen access to lymphoid system and it occurs at the peripheral organs ( e.g.. thyroid, pancreas).
  • Peripheral anergy: its mechanism is cellular inactivation by weak signalling without co-stimulus and it occurs at the secondary lymphoid tissues.
  • Regulatory cells: its mechanism is suppression by cytokines, intercellular signals and it occurs at the secondary lymphoid tissue and sites of inflammation.
    -Cytokine deviation: its mechanism is differentiation of th2 cells, limiting inflammatory cytokine secretion and it occurs at the secondary lymphoid tissues and sites of inflammation.
  • Clonal deletion: its mechanism is apoptosis post-activation and it occurs in the secondary lymphoid tissue and sites of inflammation.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Describe the postulated mechanisms of autoimmunity?

A

-Genetic susceptibility: Here the genes are affected and hence there is failure to self-tolerance which causes self-reactive lymphocytes to form and activation of these self-reactive lymphocytes cause tissue injury resulting in autoimmune diseases.
- Infection, inflammation: there is an infection or inflammation which occurs, this results in activation of APCs and influx of self-reactive lymphocytes into the tissues, activation of these self-reactive lymphocytes causes injury to the tissues and hence results in autoimmune diseases.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What are the different ways in which autoimmunity occurs?

A

-Induction of co-stimulators on APCs: here, an APC with a self antigen is affected by a microbe which then activates the APC to possess co stimulatory receptors like B7 which binds to the CD28 on the self-reactive T cells and B cells and cause autoimmunity.
- Molecular mimicry: A virus or a microbe resembles a self-antigen and hence activates a self-reactive immune cell causing autoimmunity.
Epitope spreading: autoantibodies spread and causes autoimmunity which leads to more inflammation and prolonged diseases in autoimmunity.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Describe the role of T lymphocytes in autoimmune damage?

A
  • CD4 cells polarised toward TH1 responses via cytokines.
  • CD8 cells activated to become cytotoxic T cells and cause direct cytosis.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What is the role of autoantibodies in immune damage?

A

Circulating autoantibodies can:
- activate the complement system leading to cell lysis.
- Interact with cell receptors.
- Cause toxic immune complexes.
-cause antibody dependent cellular toxicity.
- penetration into living cells.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Describe the non-specific way autoimmune damage occurs?

A

recruitment of inflammatory leukocytes into autoimmune lesions.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What are the common autoimmune diseases and examples

A
  • systemic autoimmune disease; eg rheumatoid arthritis and lupus
    -Organ specific autoimmune disease: eg myasthenia gravis, grave’s disease and autoimmune diabetes.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Describe the organ specific autoimmunity?

A
  • Accounts for 5-10% of all diagnosed cases of diabetes.
    -Autoantibodies against nicotinic acetylcholine receptors are made.
  • The antibodies mimic a ligand, which causes continual stimulation of the thyroid cells.
    -What initiates this disease is not known.
    -Maybe viral infections are involved in triggering this immune response.
  • Autoantibodies have been implicated including glutamic acid decarboxylase (GAD) and insulin itself.
    -Ion channel which functions as a receptor in muscle, receives input from motor neurons at the neuromuscular synapse and induces muscle contraction.
  • Autoantibodies are directed against the receptor for thyroid-stimulating hormone (TSH)
  • Cell mediated attack on the islets of Langerhans in the endocrine pancreas results in the death of the insulin-producing beta-cells.
    -Causes severe muscle weakness.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What are the conventional therapies autoimmune diseases?

A
  • Anti-inflammatory drugs eg aspirin,
    ibuprofen and corticosteroids.
  • Immunosuppressive drugs: inhibition of lymphocyte proliferation. Ciclosporin A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What are the non-specific ways to control autoantibodies?

A
  • Infusion of intravenous immunoglobulin from a group of healthy donors.
  • plasmapheresis: Removal of circulating antibodies but this is short term.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What are the symptoms of inflammation?

A

-Redness
-Heat
-swelling
- Pain
- Loss of function.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What are the causes of inflammation?

A
  • Response to cellular insult by; infectious agents, toxins, physical stresses.
  • Protective response: ultimate goal to remove initial cause of injury and consequences of injury- the necrotic cells and tissues.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What happens during inflammation? What are the different stages and what cells are involved?

A

Inflammation is made up of two main parts, vasculature and cellular.
During the vasculature phase, the toxin enters the cell and causes an acute phase reaction which causes transient vasoconstriction followed by cytokine mediated vasodilation of the afferent blood vessels which rashes a lot of blood to the site, as the blood vessel dilates, it becomes leaky and causes fluids to leak into tissues which shows the classic signs of inflammation, redness, swelling, heat, pain and in some serious ones loss of function. At this stage also there are release of po-inflammatory mediators like cytokines like il-1, il-6 and tnf a which causes acute phase proteins in the liver. Also Nf kB causes transcription of many pro – inflammatory mediators like adhesion molecules, mmps, chemokines and cytokines. As this is happening, activation of the complement, coagulation, fibrinolytic and kinin system also causes which then results in the attraction of leukocytes
During the cellular phase, chemoattractant are released from the endothelial cells which attracts the leucocytes to roll, slow roll and attach the adhesion molecules and causes transmigration into the site. Chemokines are released and the leukocytes find the microbes through chemotaxis . the phagocytes undergo phagocytosis and kill microbes releasing exudates which cause more swelling. After this there is tissues repair and release of anti inflammatory mediators to cause resolution. Eg solution adhesion molecules, timps, il-10, plasma molecules, resolvins and protectins.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Describe the vascular phase of inflammation including all the pro-inflammatory mediators and how they are involved?

A

A bacteria which contains an endotoxin (lipopolysaccharide) enters the body and it starts to damage the tissues and activates the mast cells. The mast cells release, histamine, prostaglandins and leukotrienes. kininogen is also converted to bradykinin, phospholipase A2 in response to the stimulus converts phospholipids to arachidonic acid which through lipoxygenases forms more leukotrienes and through cyclooxygenases forms prostaglandins. This causes an acute phase reaction which results in the transient vasoconstriction of the afferent vessels followed by cytokine mediated vasodilation of the blood vessels allowing the blood vessel to dilate and and become leaky. This forces more blood to the site causing leakage of fluid into the tissue at the site which then results in the classic symptoms of inflammation, redness, pain (through two ways of either the fluid pressing on the pain receptors of bradykinin activating the pain receptors), swelling, heat and loss of function. There is an activation of Nf KB which is a transcription factor that binds to the response elements in the nucleus causing the transcription and release of other pro-inflammatory mediators like adhesion molecules, cytokines (il-1, il-6 and TNF alpha), mmps. In addition to that there is activation of the complement, coagulation and fibrinogen systems. The cytokines IL-1, IL-6 and TNF alpha all can cause vasculature at the blood vessels, activate the release of acute phase proteins at the liver and in the bone marrow release more lymphoid cells ( B cells and T cells). Adhesion molecules like P selectins, ICAMS, e-selectins and PECAMS. Inflammatory peptides like C3a and C5a which are chemoattractant attract leukocytes to the site and once they get there they attach to the selectins, and ICAMS which are adhesion molecules and causes rolling, slow rolling completely stopping (Migration) As it stops, it squeezes through the gaps in between the blood vessels through a process of diapedesis by reacting with the PECAMS. The leukocytes are now in the tissue.
Also since the bacteria has an endotoxin, it is pyrogenic and can cause fever.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

What is the process that leads to a fever?

A

A bacteria which contains an endotoxin comes inside the cell. Macrophages phagocytose the bacteria and in response releases IL-1.IL-1 travels to the hypothalamic site of the brain causing the release of prostaglandin (PGE2) which resets the thermostat of the brain causing a change in the temperature of the body to make it an unconducive environment for the bacteria.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

What are the pro-inflammatory mediators?

A
  • Kinins
  • complement factors
    -Cytokines (Pro-inflammatory; IL-1, IL-6 and TNFa. chemokines- CXCL-8, CCL2, CCL5 etc. Growth factors- M-CSF, GM-CSF etc)
  • Adhesion molecules (ICAM, VCAM, PECAMS, selectins)
    -MMPs (MMP-1,2,9 etc)
  • Acute phase proteins
  • Prostaglandins-local
  • clotting factors
    -Histamine
    -Coagulation factors
  • chemokines
23
Q

What is the sequence of the inflammatory response?

A
  • Insult by trauma or pathogen causes acute phase reaction.
  • Platelet adhesion, transient vasoconstriction of the efferent vessels.
    -Cytokine-induced vasodilation of the afferent vessels.
  • Activation of the complement system, coagulation, fibrinolytic and kinin systems.
  • Leukocyte adhesion
  • Increase vascular permeability and extravasation of serum proteins (exudate) and leukocytes (neutrophils, macrophages, lymphocytes) with resultant tissue swelling.
  • Phagocytosis of foreign material with pus formation.
  • Wound healing and remodelling.
24
Q

What are acute phase proteins (APPs) and how they involved in inflammation?

A

They fluctuate in response to tissue injury and infections. Usually made by hepatocytes. synthesized in response to pro-inflammatory cytokines and include;
- Creatine Reactive Protein (CRP): Opsonin ( labelling pathogens so cells can come and eat them up).
- Fibrinogen: Coagulation factors.
- Serum Amyloid A: cell recruitment and MMP inducer.
- Complement factors: Opsonin, lysis, clumping, chemotaxis.
- Haptoglobin and ferritin: Bind haemoglobin or Fe.

25
Q

What are pro-inflammatory cytokines and its functions?

A
  • IL-1; vasculature (inflammation), hypothalamus (fever), liver (induces APP).
  • TNF a; vasculature (inflammation) , liver (induction APPs, induction of cell death, neutrophil activation, cachexia.
  • IL-12; NK cells, promotes TH1 subset of T lymphocytes (pro-inflammatory).
  • IL-6; Liver (induces APP), influences adaptive immunity (proliferation and antibody secretion by B cells).
  • Interferon alpha and beta (IFN a/b): induces antiviral state, activates NK cells.
26
Q

What are the chemokines and their sub families?

A

There are four 4 sub families of chemokines (CC, CXC, C, CXXXC which bind to G-protein coupled receptors (CCRS, CXCRS, XCRI,CX3CR1)
They act on different immune cell types
- Interleukin 8 (CXCL8) attracts neutrophils .
- Monocyte chemotactic protein 1 (MCP1 / CCL2) attracts monocytes.
- Eotaxin (CC41) attracts eosinophils etc.
There are redundancy and overlapping functions which means quite a lot of receptors can bind to there chemokines.

27
Q

What are adhesion molecules?

A

They are transmembrane receptors that bind either to other cells or to the extracellular matrix
four main classes;
- Ig superfamily eg VCAM-1, ICAM-1, LFA-2
- Cadherins eg E,P, N (cell-cell adhesion)
- Selectins- E,P,L - recognise carbohydrates.
- Integrins -8 subfamilies , eg a 4B (ECM and cell-cell)

28
Q

What are metalloproteinases involved in inflammation?

A

Proteases whose catalytic function requires metal, usually zinc
Three main families
- MMPs: they degrade and remodel extracellular matrix, create chemokine gradients.
- ADAMS: cleave cytokine and adhesion molecule receptors from cell surface.
- ADAMTs: cleave receptors also degrade proteoglycans.

29
Q

What are extracellular matrix proteins(ECM)?

A
  • Collagen type I, II and III- fibrillar found in bone, skin and cartilage.
  • Collagen type IV-basement membrane.
  • Laminin, Elastin, proteoglycans, aggrecan, fibronectin, matrillin, Nidogen.
30
Q

What are NF-kB and how are they activated?

A

They are a family of transcription factors that regulate hundreds of inflammatory mediators including cytokines, chemokines, adhesion molecules, MMPs, growth factors and APPs.
In absence of extracellular stimulus, NF-kB is binded to IkBa which inhibits the Nf-kB which is a transcription factor.

31
Q

What are the anti-inflammatory mediators and how they are involved in resolution?

A
  • anti-inflammatory cytokines- IL-10 and IL-4
  • Soluble adhesion molecules that bind to the adhesion molecules and hence prevents other cells from binding.
  • TIMPs: inhibit MMPs.
  • Plasmin activation system: clot reduces.
  • Opioid peptides: counteract pain.
    -Resolvins/protectins: anti-inflammatory lipid mediators
32
Q

What are the differences between acute and chronic inflammation?

A

-Acute inflammation is most needed and can have resolution. Necessary part of immune response , excessive leads to organ failure and death.
- Chronic inflammation is not needed and can sometimes have no resolution. It is the inappropriate with tissue destruction. leads to disease (autoimmune, neurodegenerative, chronic age- related disorders etc.

33
Q

What are the results of inflammation with no resolutions?

A
  • chronic inflammation.
  • Abscess formation.
  • Excess scarring.
  • Autoimmunity
34
Q

What are DMARDs and some examples of them?

A

Disease modifying antirheumatic drugs are drugs that work on the autoimmune disease itself and causes immunosuppressive effects, e.g. methotrexate, ciclosporin A, leflunomide and azathioprine

35
Q

How does methotrexate work?

A

Methotrexate is a competitive inhibitor for folic acid on the enzyme DHFR. DHFR converts DHF to THF which will then be converted to N5,N10 methylenetetrahydrofolate and hence used by thymidylate synthase to make thymine from the product of converting dump to dtmp. This gives methotrexate the ability to inhibit the de novo synthesis of pyrimidines. Methotrexate can also inhibit de novo synthesis of purines by inhibiting the enzyme AICART and hence affects the uptake of adenosine.

36
Q

How does the structure of methotrexate link to its function?

A

Methotrexate consists of a ptegly ring, p amino benzoic acid and a glutamic acid. The structure of methotrexate resembles that of folic acid but has much higher affinity to DHFR than folic acid. Methotrexate has a low lipid solubility which means it cannot cross the blood-brain barrier. Also the polyglutamate group means it can be taken up into cells via the folate pathway and allow it to swell in cells meaning it can still be in cells for weeks and months even after the systemic methotrexate has cleared.

37
Q

What are the side effects of methotrexate and how can they be managed?

A

Some side effects of methotrexate are bone marrow depression, GI effects and rash. This can be managed by giving supplements like folic acid to the patient which allows the patient to take in more folic acid. Also in severe cases, leucoorcein which is an active form of folic acid is given which means it bypasses the DHFR and goes to the thymidylate synthase and allows it to minimise the effects of methotrexate. Also low doses of methotrexate are given in autoimmune diseases. Patients are also advised regular blood checks.

38
Q

How does ciclosporin A work?

A

Ciclosporin A is a drug which was found by sandoz and is metabolised by P450 enzymes meaning it can lead to drug interactions. Ciclosporin A prevents the proliferation of B and T cells by inhibiting both the production of Il-2 and expression of IL-2 receptors. This results in decreased clonal proliferation of T cells, reduced induction and clonal proliferation of cytotoxic T cells from CD8+ precursor T cells, reduced function of the effector T cells responsible for cell-mediated responses and some reduction of T cell dependent B cell responses.

39
Q

How is ciclosporin administered and why?

A

The structure of ciclosporin A does not obey the Lipinski’s rule but what helps is the balance between the lipophilicity and hydrophilicity which is enough for the drug to cross the gut wall. Ciclosporin A is absorbed poorly in the mouth so it is given orally in a more readily absorbed formulation or by IV. After oral administration, peak plasma concentrations are usually attained in about 3-4 h and has a half-life of approximately 24h. Ciclosporin A accumulates in most tissues at concentrations three to four times that seen in the plasma.

40
Q

What are some side effects of ciclosporin A?

A
  • nephrotoxicity but is unconnected with calcineurin inhibition.
  • Hepatotoxicity
    -Hypertension.
41
Q

How does leflunomide work in rheumatoid arthritis?

A

Leflunomide is a drug that converts to a metabolite (teriflunomide) in the body and it affects the active T cells and not the resting T cells. This is because the resting T cells use the salvage pyrimidines whiles the active T cells use de novo synthesis of pyrimidines in their function. Leflunomide blocks the enzyme dihydroorotate dehydrogenase which is used in the de novo synthesis of pyrimidines which are used by active T cells.

42
Q

What are some side effects of leflunomide?

A
  • alopecia
  • diarrhoea
    -raised liver enzymes
  • Risk of hepatic failure.
43
Q

What are the fatty acid cyclo-oxygenase (COX) enzymes?

A

They are enzymes that are found in the arachidonic pathway. There are two isoforms cox-1 which is more constitutive in most tissues and mostly functions in house keeping roles(homeostatic roles) and cox-2 which is constitutive in the brain and renal but inducive and not mostly found but released in response to inflammation and infection.

44
Q

How do cox enzymes work?

A

They both work by catalysing two oxygen molecules to two of the unsaturated carbon double bonds in arachidonic acid forming the unstable endoperoxides prostaglandins PGG2 and to PGH2 which are then converted by endoperoxide isomerase or synthase to the prostaglandins PGE2, prostacyclin( PGI2), PGF2a, PGD2 and thromboxane.

45
Q

What are the different effects that the prostaglandins have when released by Cox-1 compared to cox-2?

A

Cox-1 is a more homeostatic enzyme and when it releases PGE2 it is used in the GI, when it releases PGI2 it allows GI, kidney function, thrombocyte function, blood flow regulation and when it releases TXA2 it allows thrombocyte function but when cox-2 releases PGE2,PGI2 and TXA2 it causes pain, inflammation and fever.

46
Q

What are some actions of prostanoids?

A
  • PGD2 causes vasodilation, inhibition of platelet aggregation, relaxation of the GI and uterine muscle and modification of release of hypothalamic/pituitary hormones and also has bronchoconstrictor effect at Tp receptors. It can also activate chemoattractant receptors on some leukocytes.
  • PGF2a causes uterine contraction in humans and also vasoconstriction. When inflammation occurs, it is released in high amounts by the cox-2.
    -TXA2 causes vasoconstriction, platelet aggregation and bronchoconstriction. When inflammation occurs it is released im high amounts by the cox-2.
    -PGE2 which is the predominant inflammatory prostanoid has functions at different EP receptors; at EP1 it causes the contraction of bronchial and GI smooth muscle, at EP2 it causes bronchodilation, vasodilation, stimulation of intestinal fluid secretion, at EP3 it causes contraction of intestinal smooth muscle, inhibition of gastric acid, at EP4 it causes similar effects at EP2.
47
Q

What are the functions of different prostanoids in both acute and chronic inflammation?

A

In acute inflammation, PGE2 and PGI2 are generated in local and blood tissues whiles the mast cells mainly releases PGD2.
In chronic inflammation, cells of the monocyte/macrophage series release PGE2 and TXA2 which exert some ying-yang effect stimulating some responses and reducing some.

48
Q

What are the therapeutic effects of Cox-inhibitors?

A
  • In anti-inflammatory action: the decrease in PGE2 and PGI2 reduces vasodilation and indirectly reduce oedema.
  • In analgesic effect: decreased prostaglandin means less sensitivity of the nociceptive receptors to bradykinin and 5-hydrooxytryptamine. Also less vasodilation mean less compression of the pain receptors and hence less pain.
  • In antipyretic effects: iL-1 causes the release of prostaglandins in the CNS where they elevate the hypothalamic set point for temperature control.
49
Q

What are some side effects of COX inhibitors?

A

-Dyspepsia, nausea, vomiting
- skin reactions
- liver disorders (rare)
- bronchospasm
- adverse cardiovascular effects.

50
Q

What are some clinical uses of NSAIDs?

A

-Antithrombic: aspirin used for some patients of arterial thrombosis. Other NSAIDs that cause less profound inhibition of platelet thromboxane synthesis than that of aspirin increase the risk of thrombosis and should be avoided in high-risk individuals if possible.
- Analgesia: short teem use paracetamol and ibuprofen, aspirin* (not used for pain often)
For chronic pain: naproxen
-anti-inflammatory: ibuprofen, naproxen.
-Antipyretic: paracetamol

51
Q

How is the activation of NFκB involved in the inflammatory response?

A

Nf-kB is a family of transcription which regulates gene expression. Without an extracellular stimulus, it is bound to IkB which is an inhibitor of Nf-kB. When there is a stimulus, IkB is phosphorylated and hence leaves Nf-kB which goes into the nucleus and bind to response elements causing the transcription and release of pro-inflammatory mediators like cytokines, chemokines, adhesion molecules and MMPs

52
Q

Which mediators are important in resolution?

A

The mediators involved in resolution are the anti-inflammatory mediators like anti-inflammatory cytokines like Il-10(a regulatory cytokine which prevents macrophage activation), Il-4. Also TIMPs which inhibits MMPs by deactivating them, soluble adhesion molecules which bind to adhesion molecules and prevents the cells from binding to them, Resolvins and protectins which are proteins that helps get rid of the clots, opoid peptides which help prevent pain.

53
Q

Describe the main differences between acute and chronic inflammation?

A

Acute inflammation is the type of inflammation which is most needed and also has a resolution, It mostly has a starting point either being injury or trauma but chronic inflammation is the inflammation which is mostly not needed and has no resolution, also it mostly does not have a starting point and is a build up.

54
Q

Which events drive autoimmune diseases in your body?

A

Fundamentally we have a failure in self-tolerance which is caused by.
- Genetic background(susceptibility); MHC class II. Targeting one gene is not therapeutically good because there are different polygenic genes which means autoimmune patients will develop different polymorphisms which make targeting one gene difficult.
- Infection or inflammation.

55
Q

How can autoantibodies contribute to the symptoms experienced in an autoimmune disease?

A

Circulating autoantibodies can be caused by failure in B cell tolerance which can then,
- activate the complement system and result in inflammation, clotting, cell lysis.
- Toxic immune complexes.
- Reacting with receptors on cells and causing damage.
- leaking in tissues and causing immune response there.

56
Q

Why do we need central as well as peripheral tolerance?

A

Central and peripheral tolerance and needed because not all self-antigens are present in the bone marrow and the thymus where central tolerance occurs meaning not all your self antigens in the body may be involved in the presenting stage of development of B and T cells.
Also, there is a threshold for activation via self-antigen presenting and hence some weak autoreactive cells can survive and move into the periphery.

57
Q

Discuss why gene therapy is unlikely to be of significant benefit in autoimmune diseases

A

Targeting one gene is not therapeutically good because there are different polygenic genes which means autoimmune patients will develop different polymorphisms which make targeting one gene difficult.

58
Q

What conventional treatment options are there for treating an immune disease?

A

The conventional treatment options are anti-inflammatory drugs like NSAIDs (which blocks the COX enzymes) and corticosteroids (which prevents the transcription of inflammatory mediators), immunosuppressive drugs like DMARDs which involves methotrexate (inhibition of folic acid and AICART), ciclosporin A (inhibition of differentiation of lymphocytes), azathioprine (mismatching in DNA) and leflunomide (inhibition of the de-novo synthesis of pyrimidines).

59
Q

Describe the signalling pathway that leads to the production of prostaglandins and leukotrienes.

A

There is a stimulus which activates phospholipase A2 to converts phospholipids to arachidonic acid. Arachidonic acid when acted upon by lipoxygenases then forms leukotrienes and when acted on by cyclooxygenases forms precursor for prostaglandins like PGG2 which converts to PGH2 and hence forms prostaglandins (PGE2, PG12 and TXA2)

60
Q

Explain the different roles COX-1 and COX-2 play in the production of the lipid mediators

A

COX-1 is mostly a homeostatic enzyme which plays a role in homeostatic control and when it forms PGE2 allows GI effects, PGI2 allows Gi, kidney function, regulation of blood flow and thrombocyte function and TXA2 allows thrombocyte function but for COX-2 mostly in response to inflammation. When PGE2, PGI2 and TXA2 then causes pain, fever, and inflammation.

61
Q

What is the epidemiology of RA?

A

-It affects between 0.3 and 1.5% of the population.
- If affects 600,000 (1%) of the UK.
- Most sufferers develop RA between the ages of 25 and 50.
- It is more common in females than males.
- The prevalence of RA is estimated to be about 0.5 to 1% of adult population.
- The ratio of women to men who have RA is 2-3 to 1.
- The concordance rate of twins is about 15-20% in RA. There are other genes related to RA including STAT4 (signal transducer and activator of transcription 4), TRAF1/C5 (tumor necrosis factor-receptor associated factor 1/complement component 5), and PTPN22 (protein tyrosine phosphatase, non-receptor type 22).

62
Q

What is the pathophysiology of RA?

A

-Initiation phase: there is an injury or infection which causes the citrullination of self antigens to seen as non-self.
- Inflammation phase: APCs with the citrullinated self antigens present to the B and T cells causing clonal expansion of the B and T cells without sufficient control from the Tregs cell.
- Self perpetuating phase; the inflammation of the synovium causes the exposure of the unseen antigens to be seen by immune cells causing the infiltration of more immune cells into the synovium causing more inflammation.
-Destruction phase: cytokines IL-1, IL-6 and TNFa activate the synovial fibroblast and the osteoclast causing damage to the bone and cartilage.